ARTICLE | Clinical News
Ofirmev regulatory update
November 8, 2010 8:00 AM UTC
FDA approved an NDA from Cadence for Ofirmev IV acetaminophen to treat pain and fever. As part of the approval, Cadence will conduct a post-marketing efficacy study of Ofirmev in infants and neonates. Cadence plans on launching Ofirmev in the U.S. in 1Q11. ...